COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

Search

Novo Nordisk A-S (Class B)

Chiusa

490.95 3.11

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

484.25

Massimo

492.1

Metriche Chiave

By Trading Economics

Entrata

804M

29B

Vendite

-7.6B

78B

P/E

Media del settore

20.239

51.198

EPS

6.53

Rendimento da dividendi

3.33

Margine di Profitto

37.182

Dipendenti

77,406

EBITDA

4.1B

39B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+9.53% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.33%

2.40%

Utili prossimi

6 ago 2025

Prossima data del Dividendo

18 ago 2025

Prossima data del' Ex Dividendo

14 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-8B

2T

Apertura precedente

487.84

Chiusura precedente

490.95

Novo Nordisk A-S (Class B) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 mag 2025, 11:36 UTC

Notizie principali

Novo Nordisk CEO to Step Down Amid Market Challenges

12 mag 2025, 09:36 UTC

I principali Market Mover

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 mag 2025, 11:29 UTC

Notizie principali
Utili
I principali Market Mover

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7 mag 2025, 07:05 UTC

Utili

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7 mag 2025, 06:19 UTC

Utili

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

3 giu 2025, 15:03 UTC

Acquisizioni, Fusioni, Takeovers

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29 mag 2025, 01:00 UTC

Notizie principali

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 mag 2025, 14:08 UTC

Utili

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 mag 2025, 07:43 UTC

Discorsi di Mercato

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 mag 2025, 18:35 UTC

Notizie principali

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mag 2025, 17:34 UTC

Notizie principali

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 mag 2025, 13:42 UTC

Azioni calde

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mag 2025, 13:27 UTC

Discorsi di Mercato

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 mag 2025, 13:15 UTC

Notizie principali

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 mag 2025, 12:17 UTC

Utili

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mag 2025, 18:45 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mag 2025, 12:07 UTC

Discorsi di Mercato

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mag 2025, 07:20 UTC

Discorsi di Mercato

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 mag 2025, 15:13 UTC

Utili

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 mag 2025, 13:56 UTC

Utili

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mag 2025, 13:45 UTC

Utili

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 mag 2025, 11:25 UTC

Utili

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 mag 2025, 11:18 UTC

Utili

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mag 2025, 09:55 UTC

Utili

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7 mag 2025, 09:36 UTC

Utili

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7 mag 2025, 09:04 UTC

Utili
Azioni calde

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7 mag 2025, 08:10 UTC

Discorsi di Mercato

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7 mag 2025, 08:08 UTC

Discorsi di Mercato

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7 mag 2025, 07:11 UTC

Discorsi di Mercato
Utili

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

Confronto tra pari

Modifica del prezzo

Novo Nordisk A-S (Class B) Previsione

Obiettivo di Prezzo

By TipRanks

9.53% in crescita

Previsioni per 12 mesi

Media 1,162.73 DKK  9.53%

Alto 1,550 DKK

Basso 720 DKK

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novo Nordisk A-S (Class B) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

2

Mantieni

2

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.